PARIS, FRANCE, March 26, 2025 -- Altis Labs, Inc. (“Altis”) is announcing results presented at the European Lung Cancer Congress (ELCC) 2025 in Paris: IPRO-Δ enhanced survival prediction compared to standard RECIST 1.1 blinded independent central review in AstraZeneca’s Phase 3 advanced non-small cell lung cancer trial (aNSCLC), MYSTIC.

The results validate the ability of IPRO to predict overall survival in novel aNSCLC datasets. In this evaluation, Altis’ AI pipeline was applied to the Baseline, Week 6, and Week 12 CT scans of patients enrolled in the control arm of MYSTIC (n=173). AstraZeneca then independently assessed the ability of IPRO to predict OS.  The findings further support the potential for AI-powered imaging endpoints to enhance drug developers’ ability to objectively predict differences in long-term outcomes of clinical trial subjects:

• Responders per IPRO-Δ had significantly better OS compared to subjects with IPRO-Δ stable disease (HR=0.54, 95% CI: 0.31-0.92), while responders per RECIST 1.1 had no better OS than subjects with RECIST stable disease (HR=1.10, 95% CI: 0.70, 1.77).
• Stable disease subjects per RECIST 1.1 were further stratified into subgroups by IPRO-Δ, revealing better association with OS.

Dr. Omar F. Khan, a medical oncologist from Tom Baker Cancer Center, University of Calgary, presented the results at ELCC.

Access the ePoster here. 

‍